Already 3,190 people have seen this company's branding and they are being followed by 9 Storybook user.In average the company has been rated 4.3 points ja kommenteeritud 3 korda.

's activity report 2022

Artesyn Biosolutions Estonia OÜ was established in September 2016. The company is focused on the pharmaceutical and biotechnology industry. The main activity is the development, production and sale of standard and custom-made Single Use (SU) devices and the necessary components for operating these devices, which are intended for single use in the drug manufacturing process.

The components are valves made of stainless steel or plastic, silicone tubes and their supporting casings.

The devices are mainly different Single-Use filtration and process equipment (Tangential Flow Filtration,

Virus Filtration, Chromatography, Final Filtration & Bulk Fill).

The Estonian business unit provides sales and customer support, component or equipment design, project management and production service.

Artesyn Biosolutions Estonia OÜ's clients are global companies in the pharmaceutical and biopharmaceutical sector and drug industry factories.

In 2022, the main activity was continued and long-term projects were carried out for clients around the world.

At the end of 2020, Repligen Corporation (NASDAQ:RGEN) acquired ARTeSYN Biosolutions companies in the USA,

Ireland and Estonia.

More detailed information is available in the Repligen Corporation press release: https://repligen.q4ir.com/news/news-details/2020/Repligen-Corporation-

Announces-Agreement-to-Acquire-Bioprocess-Systems-Innovator-ARTeSYNBiosolutions- and-Completes-Acquisition-of-Non-Metallic-Solutions/default.asxx In September 2022, the company's business name was changed. The new company name is Repligen Estonia OÜ. In 2022,

construction of a new production building in Rae parish, Jüri, was also started. The new building will be completed in the first quarter of 2024.

At the end of the 2022 financial year, the company had 49 employees and 3 board members.

A fee was calculated for one board member.

The total labor costs including taxes were 2,842,133 euros (2021: 2,162,814 euros).

The sales revenue for the financial year was 9,560,606 euros (2021: 9,028,285 euros) and the profit was 867,637 euros (2021: profit 28,348 euros).

In 2023, the main activity will continue and the company will be integrated into the Repligen corporation.